Welcome to our dedicated page for Reviva Pharmaceuticals Holdings news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Rhea-AI Summary
RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.09%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that its CEO will present and participate in a conference panel at the H.C. Wainwright 25th Annual Global Investment Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals has completed enrollment in its Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia. The study included 402 patients from multiple sites in the US, Europe, and Asia. Topline data is expected in October 2023, and completion of a 1-year open-label extension study is expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. reported financial results for Q2 2023 and highlighted recent business developments. They expect to release topline data for the Phase 3 RECOVER trial for brilaroxazine in schizophrenia in October 2023. The company also plans to complete a 1-year open-label extension clinical trial for brilaroxazine in Q3 2024. Reviva's cash as of June 30, 2023, is approximately $11.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that their CEO will be presenting at two upcoming investor conferences in August 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals has announced that over 80% of patients have been enrolled in the Phase 3 RECOVER study for brilaroxazine, a potential treatment for schizophrenia. Enrollment is ongoing at multiple sites worldwide, and topline data is expected in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
FAQ
What is the current stock price of Reviva Pharmaceuticals Holdings (RVPH)?
The current stock price of Reviva Pharmaceuticals Holdings (RVPH) is $1.24 as of November 21, 2024.
What is the market cap of Reviva Pharmaceuticals Holdings (RVPH)?
The market cap of Reviva Pharmaceuticals Holdings (RVPH) is approximately 40.5M.
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Reviva Pharmaceuticals specializes in discovering, developing, and commercializing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases.
Where is Reviva Pharmaceuticals Holdings, Inc. located?
The company is located at 5941 Optical Ct, San Jose, California, United States.
What is Brilaroxazine (RP5063)?
Brilaroxazine (RP5063) is a versatile drug candidate intended to treat multiple neuropsychiatric conditions including schizophrenia, bipolar disorder, and Parkinson's disease psychosis, among others.
What is the focus of Reviva's current pipeline?
Reviva's current pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases.
What technology does Reviva use for drug development?
Reviva Pharmaceuticals utilizes a chemical genomics-driven technology platform and proprietary chemistry for drug development.
Who can be contacted for more information about Reviva Pharmaceuticals?
For more information, you can contact Reviva Pharmaceuticals Holdings, Inc., their Investor Relations at LifeSci Advisors, or their Media Contact, Kristin Polit.
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
Another drug candidate in Reviva's pipeline is RP1208.
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
Reviva Pharmaceuticals targets therapeutic areas within the central nervous system, inflammatory, and cardiometabolic diseases.
How can I stay updated with Reviva Pharmaceuticals' latest news?
You can visit their official website or subscribe to updates through their corporate and investor relations contacts.
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
The main contact for investor inquiries is Bruce Mackle from LifeSci Advisors, LLC.
Reviva Pharmaceuticals Holdings, Inc.
OTC:RVPH
RVPH Rankings
RVPH Stock Data
40.46M
28.50M
14.79%
30.07%
15.84%
Biotechnology
Pharmaceutical Preparations
United States of America
CUPERTINO